04/18/2026
🚨 Breaking: Federal Action Expands Psÿchede|lic Research in the U.S.
Today, the President signed an executive order directing federal agencies to accelerate research into psÿchede|lic substances, including ibogaine.
This is not just symbolic. It includes:
• Federal match funding (up to $50M) to support state-led research
• FDA clearance for clinical trials of ibogaine to begin in the U.S.
• Efforts to reduce barriers for Schedule I research
• Expanded collaboration across agencies, including the VA
• Faster review pathways for potential treatments
• Exploration of Right to Try access for eligible patients
Together, these actions signal a meaningful shift in how psÿchede|lic research is being approached at the federal level.
At the same time, this moment comes with important nuance.
Much of this work is still in early stages. Some substances, like ibogaine, remain less studied and carry known risks. And while timelines may accelerate, access will still depend on rigorous research, regulatory review, and careful implementation.
What feels clear is this:
The national conversation is evolving.
We are seeing growing alignment across researchers, clinicians, policymakers, and communities, especially around the urgent need for new approaches to mental health and addiction care.
As this field continues to develop, the role of ethical training, trauma-informed facilitation, and regulated models of care remains essential.
This is a moment to stay grounded, informed, and engaged.
How are you feeling about this news?
